Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana announced that its primary islet cell therapy, UP421, had been successfully implanted into a Type 1 diabetes patient.

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...